Goodwin-Guided Kymera Raises $150M With Share Sale
Clinical-stage biopharmaceutical company Kymera has raised $150 million through a securities purchase agreement advised by Goodwin Procter LLP, with existing and newly accredited investors, according to a Friday announcement....To view the full article, register now.
Already a subscriber? Click here to view full article